2022
Paper 07: Predictors of Return to Sport in High-Level Athletes Following Hip Arthroscopy for Femoroacetabular Impingement
Monahan P, Jimenez A, Owens J, Maldonado D, Saks B, Sabetian P, Ankem H, Lall A, Domb B. Paper 07: Predictors of Return to Sport in High-Level Athletes Following Hip Arthroscopy for Femoroacetabular Impingement. Orthopaedic Journal Of Sports Medicine 2022, 10: 2325967121s00545. PMCID: PMC9150233, DOI: 10.1177/2325967121s00545.Peer-Reviewed Original ResearchPostoperative alpha angleNon-Arthritic Hip ScoreAlpha angleHip scoreHip Outcome Score-Sport SpecificMultivariate logistic regression modelHarris hip scorePrimary hip arthroscopyMultivariate logistic regressionSignificant predictorsReceiver operator characteristic analysisOperator characteristic analysisLogistic regression modelsHigh-level athletesPostoperative PROsPostoperative patientsOutcome scoresMean ageRadiographic factorsHip arthroscopyHigh school sportsPatientsAcceptable discriminationLogistic regressionROC curve
2021
Postoperative Alpha Angle Is Predictive of Return to Sport in Athletes Undergoing Hip Arthroscopy for Femoroacetabular Impingement
Monahan PF, Jimenez AE, Owens JS, Lee MS, Maldonado DR, Saks BR, Lall AC, Domb BG. Postoperative Alpha Angle Is Predictive of Return to Sport in Athletes Undergoing Hip Arthroscopy for Femoroacetabular Impingement. Arthroscopy The Journal Of Arthroscopic And Related Surgery 2021, 38: 1204-1214. PMID: 34571180, DOI: 10.1016/j.arthro.2021.09.015.Peer-Reviewed Original ResearchConceptsPostoperative alpha angleHip Outcome Score-Sport SpecificAlpha angleHip scoreHip arthroscopyPostoperative patient-reported outcome scoresPostoperative patient-reported outcomesPatient-reported outcome scoresMultivariate logistic regression modelHarris hip scoreNonarthritic Hip ScorePrimary hip arthroscopyPatient-reported outcomesMultivariate logistic regressionReceiver operator characteristic curveSignificant predictorsReceiver operator characteristic analysisOperator characteristic curveOperator characteristic analysisHigh rateLogistic regression modelsHigh school athletesOutcome scoresMean ageRadiographic factorsUpdated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology 2021, 39: 2247-2256. PMID: 33999652, PMCID: PMC8260904, DOI: 10.1200/jco.21.00280.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoadjuvant TherapyPositron Emission Tomography Computed TomographyPredictive Value of TestsRadiopharmaceuticalsReceptor, ErbB-2Time FactorsTrastuzumabTreatment OutcomeUnited StatesConceptsPositron emission tomography-computed tomographyFluorodeoxyglucose positron emission tomography-computed tomographyHER2-positive breast cancerEmission tomography-computed tomographyPathologic complete responseTomography-computed tomographyStandardized uptake valueBreast cancerComplete responseUptake valuePercent changeOne-sided type ITumor maximum standardized uptake valueHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Maximum standardized uptake valuePathological complete responseGrowth factor receptor 2Median percent reductionPositive breast cancerTailoring of therapyLean body massReceiver operator characteristic analysisFactor receptor 2Operator characteristic analysis
2020
Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.
Winer E, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Lunceford J, Karantza V, Mejia J, Cristescu R, Aurora-Garg D, Jelinic P, Huang L, Cortes J. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. Journal Of Clinical Oncology 2020, 38: 1013-1013. DOI: 10.1200/jco.2020.38.15_suppl.1013.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerTumor mutational burdenMut/MbClinical outcomesTriple-negative breast cancerChemo-treated patientsPrior systemic treatmentThird-line settingOverall study populationNumber of patientsTwo-sided p valuePD-L1 enrichmentReceiver operator characteristic analysisEstimates of efficacyOperator characteristic analysisP-valueFoundationOne CDxBaseline characteristicsMetastatic diseaseSystemic treatmentPotential positive associationTreatment armsClinical benefitCox regressionBreast cancerSmooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases
Alpert L, Al-Sabti R, Graham RP, Pai RK, Gonzalez RS, Zhang X, Smith V, Wang HL, Westbrook L, Goldblum JR, Bakhshwin A, Shetty S, Klimstra DS, Shia J, Askan G, Robert ME, Thomas C, Frankel WL, Alsomali M, Hagen C, Mostafa ME, Feely MM, Assarzadegan N, Misdraji J, Shih AR, Agostini-Vulaj D, Meis JM, Tang S, Chatterjee D, Kang LI, Hart J, Lee SM, Smith T, Yantiss RK, Hissong EM, Gao ZH, Wu J, Resnick MB, Wu EY, Pai RK, Zhao L, Doyle LA, Chopra S, Panarelli NC, Hu S, Longacre TA, Raghavan SS, Lauwers GY, Ghayouri M, Cooper HS, Nagarathinam R, Bellizzi AM, Kakar S, Hosseini M, Rong J, Greenson JK, Lamps LW, Dong Z, Bronner MP. Smooth muscle tumors of the gastrointestinal tract: an analysis of prognostic features in 407 cases. Modern Pathology 2020, 33: 1410-1419. PMID: 32051556, PMCID: PMC8405135, DOI: 10.1038/s41379-020-0492-5.Peer-Reviewed Original ResearchConceptsSmooth muscle tumorsGastrointestinal smooth muscle tumorsMuscle tumorsPrognostic featuresSmall bowelGastrointestinal tractNon-progressive tumorsProgression-free survivalSlight female predominanceDisease-related deathKaplan-Meier plotsReceiver operator characteristic analysisSoft tissue pathologistsPotential prognostic featuresOperator characteristic analysisMucosal ulcerationSerosal involvementFemale predominanceLocal recurrenceMargin statusPathologic featuresTumor sizeLarge tumorsEsophageal tumorsTumor necrosis
2015
Risk stratification of patients undergoing medical therapy after coronary angiography
Bettinger N, Palmerini T, Caixeta A, Dressler O, Litherland C, Francese DP, Giustino G, Mehran R, Leon MB, Stone GW, Généreux P. Risk stratification of patients undergoing medical therapy after coronary angiography. European Heart Journal 2015, 37: 3103-3110. PMID: 26685136, DOI: 10.1093/eurheartj/ehv674.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsCoronary artery diseaseSYNTAX scoreMedical therapyNSTE-ACSRisk stratificationSegment elevation acute coronary syndromesElevation acute coronary syndromeAdverse ischemic eventsMean SYNTAX scoreAdverse cardiac eventsAcute coronary syndromeBetter prognostic accuracyReceiver operator characteristic analysisImportant clinical implicationsStrongest predictorOperator characteristic analysisACUITY trialCoronary syndromeInitial angiogramCardiac eventsIschemic eventsPrognostic impactArtery diseaseCoronary angiography
2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS
Fitian A, Nelson D, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS. Liver International 2014, 34: 1428-1444. PMID: 24661807, PMCID: PMC4169337, DOI: 10.1111/liv.12541.Peer-Reviewed Original ResearchMeSH Keywords12-Hydroxy-5,8,10,14-eicosatetraenoic AcidAmino AcidsBile Acids and SaltsCarcinoma, HepatocellularChromatography, High Pressure LiquidDicarboxylic AcidsGas Chromatography-Mass SpectrometryHepatitis CHumansHydroxyeicosatetraenoic AcidsLiver CirrhosisLiver NeoplasmsMetabolomeMetabolomicsMultivariate AnalysisROC CurveSphingosineTandem Mass SpectrometryXanthineConceptsPresence of HCCHepatocellular carcinomaUPLC/MS-MSHCC patientsMetabolic alterationsHepatitis C cirrhosisBile acid metabolismHallmarks of HCCMetabolomic profilingAcid metabolismReceiver operator characteristic analysisOperator characteristic analysisGlobal metabolic alterationsMetabolic pathway disturbancesC cirrhosisHCV cirrhosisHepatitis CMetabolic disturbancesHCC developmentSerum metabolomeHealthy volunteersEicosanoid pathwayCirrhosisPathway disturbancesBile acids
2010
S100b Immunoassay: An Assessment of Diagnostic Utility in Minor Head Trauma
Kotlyar S, Larkin GL, Moore CL, D’Onofrio G. S100b Immunoassay: An Assessment of Diagnostic Utility in Minor Head Trauma. Journal Of Emergency Medicine 2010, 41: 285-293. PMID: 20692788, DOI: 10.1016/j.jemermed.2010.05.040.Peer-Reviewed Original ResearchConceptsMinor head traumaHead traumaS100B levelsUnited States emergency departmentsMean age 48 yearsMedian S100B levelStates emergency departmentsProspective observational studyGlasgow Coma ScaleAge 48 yearsLoss of consciousnessNon-specific markerReceiver operator characteristic analysisEnzyme-linked immunosorbentOperator characteristic analysisCentral nervous system peptideHCT patientsComa ScaleIntracranial injuryEmergency departmentHead injuryObservational studyUnnecessary headDiagnostic utilityInjury
2000
The Stroke Prognosis Instrument II (SPI-II)
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Roberts R, Gent M, Rothwell P, Sacco R, Liu R, Boden-Albala B, Horwitz R. The Stroke Prognosis Instrument II (SPI-II). Stroke 2000, 31: 456-462. PMID: 10657422, DOI: 10.1161/01.str.31.2.456.Peer-Reviewed Original ResearchConceptsRisk groups ICongestive heart failurePooled rateRisk groupsGroup IPrior strokeSPI-IIHeart failureOutcome ratesTest cohortPooled outcome ratesTransient ischemic attackCoronary artery diseasePatient risk groupsStroke Prognosis Instrument IIReceiver operator characteristic analysisOperator characteristic analysisIschemic attackIschemic strokeArtery diseaseIndex eventPatient counselingNew predictive variablesStrokeTotal score
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply